RFReza Faramarzzadeh

Reza Faramarzzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reza Faramarzzadeh has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dysbiosis of the oral microbiome and cardiovascular risk; from endothelial dysfunction to systemic inflammation

    by Ali Farmanieh, Afsoon Jalali Ara, Sara Rashki Ghalehno, Parsa Malek, Mitra Rostami, Seyed Sasan Amiri, Negar Khaneshi, Reza Faramarzzadeh, Golara Abdolmohammadi, Maryam Onsori

    A growing body of evidence implicates dysbiosis of the oral microbiome as a significant, modifiable risk factor for cardiovascular disease. This dysbiosis, often manifesting as periodontitis, initiates local inflammation and tissue destruction, however its systemic consequences are profound. Key mechanisms linking oral dysbiosis to cardiovascular disease involve the induction of endothelial dysfunction and chronic systemic inflammation. Pathogens and their virulence factors enter the bloodstream through inflamed periodontal tissues, directly impairing endothelial nitric oxide production and bioavailability, promoting vasoconstriction, leukocyte adhesion, and a pro-thrombotic state. Concurrently, microbial components activate innate immune receptors on endothelial and immune cells, triggering sustained release of pro-inflammatory cytokines and acute-phase proteins. The low-grade, systemic inflammation accelerates atherosclerosis by promoting foam cell formation, plaque instability, and vascular remodeling. Epidemiological studies consistently associate periodontitis with increased risks of myocardial infarction, stroke, and atherosclerosis severity, independent of traditional risk factors.


  • Open Access

    Relationship between neutrophil percentage to albumin ratio and cardiovascular disease mortality in chronic kidney disease patients; a systematic review and meta-analysis

    by Mohammad Rostamzadeh, Yaser Abolhasani, Amir Heidari, Abdolmohammad Ranjbar, Ali Emadzadeh, Maede Safari, Niloofar Khosravi, Samaneh Zandifar, Roozbeh Roohinezhad, Mohamadnavid Vanda, et al.

    Introduction: Chronic inflammation plays a significant role in cardiovascular disease (CVD)–related mortality among patients with chronic kidney disease (CKD). The neutrophil‑to‑albumin percentage ratio (NPAR) has emerged as an indicator of an individual’s inflammatory status. This study aimed to investigate the association between elevated NPAR and the risk of CVD mortality in patients with CKD. Materials and Methods: The study was conducted in accordance with the PRISMA reporting guidelines. Comprehensive searches were performed across the Cochrane Library, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, up to 30 January 2026. All statistical analyses were carried out using STATA version 14. Results: Compared with lower NPAR values, elevated NPAR was associated with a higher risk of cardiovascular mortality (OR = 1.54; 95% CI: 1.33–1.78) and all‑cause mortality (OR = 1.62; 95% CI: 1.40–1.89) in patients with CKD. In addition, higher NPAR increased the risk of CVD‑related death among patients undergoing hemodialysis (OR = 1.66; 95% CI: 1.29–2.15) and peritoneal dialysis (OR = 1.56; 95% CI: 1.25–1.94). Furthermore, the third quartile of NPAR (OR = 1.44; 95% CI: 1.16–1.78), the fourth quartile (OR = 1.92; 95% CI: 1.61–2.30), the second tertile (OR = 1.38; 95% CI: 1.07–1.80), and the third tertile (OR = 1.97; 95% CI: 1.61–2.41) were all associated with increased CVD mortality compared with the lowest category. Elevated NPAR also increased the risk of CVD‑related mortality in both men (OR = 1.23; 95% CI: 1.04–1.45) and women (OR = 1.16; 95% CI: 1.08–1.24) with CKD. Conclusion: Higher NPAR levels were associated with an increased likelihood of cardiovascular and all‑cause mortality among individuals with CKD. As NPAR values rose, the risk of CVD‑related death increased correspondingly when compared with lower levels. In addition, cardiovascular mortality risk was greater in men than in women, and higher among patients receiving hemodialysis than those undergoing peritoneal dialysis. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420261304086) and Research Registry (UIN: reviewregistry2082) websites.

  • Cross-talk of bone remodeling and cardiac dysfunction; reimagining the bone-heart axis in atherosclerosis pathogenesis

    by Kianoush Saberi, Amir Heidari, Mohammad Rostamzadeh, Abdolmohammad Ranjbar, Faezeh Nesaei, Mohammad Parsa Mahjoob, Iman Zafar Asoodeh, Reza Faramarzzadeh, Shahnaz Sharifi

    Recent findings detected a dynamic, reciprocal relationship between bone remodeling and cardiac dysfunction, significantly influencing atherosclerosis pathogenesis. The bone-heart axis consists of bidirectional signaling of bone-derived factors and dysregulated mineral metabolism, which directly affect vascular calcification, endothelial function, and myocardial stress. Conversely, cardiac hormones and systemic inflammation modulate osteoclast/osteoblast activity. Critically, shared molecular pathways, like RANKL/RANK/OPG modulate both skeletal turnover and vascular inflammation/calcification. Pathological bone resorption releases calcium and matrix vesicles that nucleate vascular calcification, accelerating atherosclerotic plaque instability. Reimagining this axis emphasizes on osteo-immunological mechanisms with central role in cardiovascular disease progression, suggesting integrated therapeutic targets for atherosclerosis beyond traditional lipid-centric approaches.

  • Open Access

    Association of life’s essential 8 as a Cardiovascular Health Index with risk of chronic kidney disease; a systematic review and meta-analysis

    by Saeid Bejarzehi, Fatemeh Vahmani, Amir Heidari, Fariba Jafari Khabaz, Faeze Shafie Bafti, Jalal Nourmohammadi, Reyhaneh Sadeghian, Reza Faramarzzadeh, Mohammad Rostamzadeh

    Introduction: Due to the close association between chronic kidney disease (CKD) and cardiovascular disease (CVD), maintaining optimal cardiovascular health (CVH) may serve as a preventive strategy to reduce the risk of CKD and its related health burden. Therefore, this study aimed to investigate the association between Life’s Essential 8 (LE8) and the risk of CKD. Materials and Methods: This study systematically searched the Cochrane, Embase, PubMed, ProQuest, Web of Science, Scopus, and Google Scholar databases up to April 26, 2025. Data analysis was performed using IBM SPSS Statistics version 19 and STATA version 14. Results: An increase in the LE8 score was associated with a reduced risk of CKD, as indicated by the odds ratio (OR: 0.74, 95% CI: 0.67–0.82) and hazard ratio (HR: 0.60, 95% CI: 0.46–0.77). The protective effect of higher LE8 scores was observed across various subgroups: individuals aged 40–49 (OR: 0.81, 95% CI: 0.78–0.84), 50–59 (OR: 0.75, 95% CI: 0.60–0.94), males (OR: 0.81, 95% CI: 0.76–0.87), females (OR: 0.91, 95% CI: 0.87–0.95), and populations from the UK (OR: 0.60, 95% CI: 0.46–0.77), China (OR: 0.64, 95% CI: 0.63–0.65), and the USA (OR: 0.77, 95% CI: 0.72–0.81). Similarly, both cohort studies (OR: 0.66, 95% CI: 0.54–0.81) and cross-sectional studies (OR: 0.73, 95% CI: 0.66–0.81) confirmed this inverse association. Moreover, compared to low LE8 scores, moderate (OR: 0.58, 95% CI: 0.52–0.65) and high (OR: 0.43, 95% CI: 0.35–0.53) LE8 scores were significantly associated with reduced CKD risk. Conclusion: An increase in the LE8 score was associated with a greater reduction in the risk of CKD in older age groups compared to younger ones, and in men compared to women. Moreover, the higher the LE8 score, the lower the risk of developing CKD. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251043587) and Research Registry (UIN: reviewregistry2006) websites.

  • The Relationship between Using Renin-Angiotensin System Inhibitors with Mortality of Atrial Fibrillation: A Systematic Review and Meta-Analysis

    by Reza Faramarz Zadeh, Shahab Masoumi, Negar Jafari, Venus Shahabi Rabori, Saeid Heidari-Soureshjani

    Background: Atrial fibrillation (AFib) is a highly prevalent cardiac arrhythmia associated with increased mortality in affected persons. Renin-angiotensin system inhibitors (RASIs) have been suggested as potential therapeutic agents for cardiovascular and renal diseases. Objectives: However, the relationship between RASIs and mortality in AFib patients remains uncertain. Therefore, the present study was designed and implemented for this purpose. Methods: We searched PubMed/MEDLINE, Embase, Web of Science (WOS), Cochrane Library, and Scopus databases for studies published until 12 February 2024 with relevant keywords. We included studies that reported mortality outcomes in AFib patients treated with RASIs and non-users. The data extraction and quality assessment processes were conducted, and subgroup analyses and sensitivity analyses were done. The data were analyzed by Stata 15 using statistical tests, such as Chi-square and I2 tests. Results: A total of 15 studies (2007-2024; n=2,178,565 patients) examined the association between RASI drugs and mortality of patients with AFib. The results indicated that compared to the control group, the odds of AFib mortality in the group receiving RASIs were equal to 0.81(95% CI: 0.71-0.92; P-value ≤0.001). The study results did not indicate publication bias (Pvalue= 0.733). During the meta-regression analysis, none of the study variables demonstrated a significant relationship with the observed heterogeneity (P-value > 0.20). Cumulative OR results showed that from 2022 onwards, there was enough evidence to confirm the relationship using RASIs with mortality of patients with AFib. Conclusion: Therefore, this meta-analysis suggests that the use of RASI drugs is associated with reduced AFib mortality. However, the authors emphasize the need for further high-quality studies and large-scale randomized clinical trials to validate these findings.

  • Open Access

    Relationship between systemic immune-inflammation Index and contrast-induced acute kidney injury in cardiovascular patients: systematic review and meta-analysis

    by Mohammad Rostamzadeh, Sholeh Ghasemi, Amir Heidari, Maytham Hameed Al-Qanbar, Maedeh Golnavaz, Roozbeh Roohinezhad, Nadia Pourghaz, Negar Jafari, Reza Faramarzzadeh

    Introduction: Contrast-induced acute kidney injury (CI-AKI) imposes high costs and various complications on individuals and society. Considering that inflammation is a significant risk factor for CI-AKI incidence, the present research aimed to investigate the relationship between the systematic immune-inflammation (SII) index and the CI-AKI risk in cardiovascular patients using the systematic review and meta-analysis method. Materials and Methods: In the present study, ProQuest, PubMed, Embase, Web of Science, Cochrane, Scopus, and Google Scholar databases were used to search for articles published until October 16, 2024. Data analysis was conducted using the STATA 14 software, and tests with P values < 0.05 were considered statistically significant. Results: There was no significant association between the SII index and risk of CI-AKI in patients who underwent carotid artery angiography (OR: 1; 95% CI: 1, 1.01) or coronary angiography (OR: 1.96; 95% CI: 0.94, 4.11). However, in patients undergoing percutaneous coronary intervention (PCI) (OR: 1.01; 95% CI: 1, 1.02), high SII index levels increased the risk of CI-AKI. High SII index levels (OR: 1.01; 95% CI: 1.01, 1.02), higher ages (OR: 1.04; 95% CI: 1.02, 1.06), high-sensitivity C-reactive protein (hs-CRP) (OR: 1.01; 95% CI: 1, 1.02), hypertension (OR: 1.63; 95% CI: 1.31, 2.03), diabetes mellitus (OR: 1.73; 95% CI: 1.12, 2.68), neutrophil to lymphocyte ratio (NLR) (OR: 1.09; 95% CI: 1.01, 1.17), and neutrophil count (OR: 1.12; 95% CI: 1.08, 1.16) increased the risk of CI-AKI in cardiovascular patients. On the other hand, estimated glomerular filtration rate (eGFR) (OR: 0.98; 95% CI: 0.98, 0.99), lymphocyte count (OR: 0.47; 95% CI: 0.31, 0.71), and hemoglobin (OR: 0.97; 95% CI: 0.96, 0.98), albumin (OR: 0.96; 95% CI: 0.93, 0.99) in individuals with CIN were lower than those in the no-CIN group. Conclusion: High systemic immune-inflammation index levels, age, NLR, hs-CRP, hypertension, diabetes mellitus, and neutrophil count were among the risk factors of CI-AKI incidence in cardiovascular patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024604243) and Research Registry (UIN: reviewregistry1904) website.


  • Open Access

    The Role of Epigenetics in Myocardial Infarction: Mechanism and Therapeutic Potential

    by Arash Amin, Mohsen Abbasnezhad, Ali Keshavarzian, Ahmadreza Badali, Roohollah Rahbani, Reza Faramarz Zadeh

    Myocardial infarction (MI), remains one of the leading causes of morbidity and mortality worldwide. As a result, understanding the underlying mechanisms of MI is crucial for developing effective therapeutic strategies. Epigenetics, which involves heritable changes in gene expression without altering the underlying DNA sequence, has emerged as a significant factor in the pathogenesis and progression of MI. Key epigenetic mechanisms such as DNA methylation, histone modifications, and noncoding RNAs (ncRNAs) have been shown to regulate genes associated with inflammation, apoptosis, fibrosis, and cardiac repair. These epigenetic alterations contribute to the complex gene-environment interactions that influence clinical outcomes in MI patients. Recent research has identified specific epigenetic changes that can serve as biomarkers for MI risk stratification, offering potential for early diagnosis and personalized therapeutic interventions. Moreover, targeting these epigenetic modifications holds promise as a therapeutic strategy to reduce myocardial damage, enhance cardiac function, and prevent adverse remodeling after MI. This review explores the mechanisms by which epigenetic regulation influences MI pathogenesis and discusses the therapeutic potential of targeting these pathways to improve patient outcomes. By integrating epigenetic therapies into clinical practice, it may be possible to revolutionize the treatment of MI, addressing the disease at its molecular roots and offering more effective, durable interventions.


  • Open Access

    How lifestyle factors can contribute to cardiovascular disease incidence; a review study

    by Negar Jafari, Soleyman Alivand, Hanieh Molaee, Venus Shahabi Rabori, Ali Asadian, Sara Abbasian, Reza Faramarzzadeh

    Cardiovascular diseases (CVDs) are a group of diseases that include cardiac and blood vessels. Lifestyle factors for cardiovascular diseases refer to the behaviors and habits that can enhance or reduce the risk of developing heart disease. In this review study, we did a comprehensive search in the online database, including PubMed, Web of Science, Scopus, and motor search engines such as Google Scholar. We investigated the studies that assessed lifestyle factors for CVD incidence. Results showed that physical inactivity, unhealthy diet, alcohol consumption, smoking, obesity, and stress are the most common lifestyle factors related to the incidence of CVDs.


  • Open Access

    Contrast-associated acute kidney injury following intravenous contrast media computed tomography; new concept and future directions: A systematic review study on emergencies patients

    by Hamidreza Khodabandeh, Arash Izadpanah Ghahremani, Ali Zolfi Gol, Negar Jafari, Hussein Soleimantabar, Venus Shahabi Rabori, Hanie Fooladi, Fariba Asadi Noghabi, Ali Erfani, Reza Faramarzzadeh

    Introduction: Computed tomography (CT) is a key method for various disorders. Image can be more quality with intravenous contrast media, however in some cases may be accompanied by a risk of kidney impairment. Objectives: This study aimed to investigate the association between acute kidney injury incidence and intravenous contrast media for CT in emergency patients. Methods and Materials: Search strategies were performed using standard keywords across international databases such as Web of Science, Scopus, Cochrane, PubMed, and Embase. Dimension, OpenGrey, DOAJ, CINAHL, and Google Scholar search engines were searched for a complete search. Additionally, manual searching was conducted using the references of related articles. Studies that reported the correlation between acute kidney injury incidence and intravenous contrast media were included in this systematic review. Results: First, 1185 studies were identified. After duplication, 533 studies remained and 417 were excluded. Out of 116 evaluated studies for retrieval, 49 were eliminated and 67 were assessed for eligibility. Ultimately, 28 studies with 48878 patients were included in the final review. Most of the studies were retrospective cohorts and have found no significant correlation between the incidence of acute kidney injury and intravenous contrast media administration (ICMA) for CT. Conclusion: Intravenous contrast media with a conventional dose for CT does not cause acute kidney injury unless in the presence of a particular condition. Registration: This study was compiled following the PRISMA checklist and its protocol was registered on the PROSPERO (CRD42023448461) and Research Registry (UIN: reviewregistry1690) websites.


  • Open Access

    The Regulation of Pyroptosis and Ferroptosis by MicroRNAs in Cardiovascular Diseases

    by Reza Faramarzzadeh, Akram Shariati, Venous Shahabi Raberi, Mehdi Masumi, Ali Tarbiat, Elham Rastgoo

    Cardiovascular diseases (CVDs) are considered the most prevalent noncommunicable disease and the leading cause of death worldwide. A plethora of evidence has revealed that microRNAs (miRNAs) could control the inhibition or progression of CVDs by regulating pivotal cell processes ranging from metabolism and homeostasis to programmed cell death (PCD). Pyroptosis and ferroptosis are two major types of nonapoptotic PCDs involved in the pathogenesis of heart failure. However, no study has discussed the crosstalk between miRNAs and these two types of PCDs in the CVDs. The current review demonstrated that different types of miRNAs can regulate both ferroptosis and pyroptosis and thereby affect CVDs progression and inhibition. Altogether, the discussed content encourages further studies to confirm that mentioned pathways are suitable to be considered as novel therapeutic approaches against CVDs.